Ausdal Financial Partners Inc. Takes $882,000 Position in McKesson Corporation $MCK

Key Points

• Ausdal Financial Partners bought 1,167 McKesson shares worth approximately $882,000 in the second quarter. Institutional investors collectively own 85.07% of the company.
• Analyst sentiment remains favorable, with 14 Buy ratings and four Holds, producing a consensus “Moderate Buy” rating and a $973.44 price target.
• McKesson exceeded quarterly earnings and revenue expectations and raised its quarterly dividend to $0.94 per share, while investors continue to weigh the $2.25 billion Precision Medicine acquisition against restructuring, pricing, and policy risks.

Ausdal Financial Partners Inc. purchased a new stake in McKesson Corporation (NYSE:MCK - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 1,167 shares of the company's stock, valued at approximately $882,000.

Several other large investors have also recently bought and sold shares of MCK. University of Texas Texas AM Investment Management Co. bought a new position in McKesson in the fourth quarter valued at about $25,000. Swiss RE Ltd. acquired a new position in McKesson during the 4th quarter valued at about $26,000. Delos Wealth Advisors LLC acquired a new position in McKesson during the 2nd quarter valued at about $27,000. State of Wyoming bought a new position in shares of McKesson in the 2nd quarter valued at about $29,000. Finally, Kingdom Financial Group LLC. acquired a new stake in shares of McKesson during the 4th quarter worth approximately $33,000. Institutional investors and hedge funds own 85.07% of the company's stock.

Analyst Ratings Changes

A number of analysts have commented on the stock. Deutsche Bank Aktiengesellschaft reaffirmed a "buy" rating and set a $875.00 target price on shares of McKesson in a report on Friday, May 8th. TD Cowen raised their price target on McKesson from $989.00 to $1,006.00 and gave the stock a "buy" rating in a research report on Thursday, August 6th. Royal Bank Of Canada initiated coverage on McKesson in a research note on Wednesday, August 19th. They set a "sector perform" rating and a $845.00 price objective for the company. Citigroup increased their target price on McKesson from $945.00 to $1,000.00 and gave the company a "buy" rating in a research note on Friday, July 24th. Finally, Barclays raised their target price on McKesson from $925.00 to $1,000.00 and gave the stock an "overweight" rating in a report on Wednesday, August 19th. Fourteen research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $973.44.

Key McKesson News

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: McKesson’s agreement to acquire Precision Medicine Group would expand its clinical research and drug-commercialization capabilities. Management expects the business to complement its oncology operations and create additional growth opportunities in specialty pharmaceuticals. Reuters: McKesson to buy Precision Medicine Group
• Positive Sentiment: Short interest in McKesson fell 33% to about 2.42 million shares as of August 14, representing just 2.1% of shares outstanding and 2.2 days of average trading volume. The reduction suggests less bearish positioning and may provide technical support for the stock.
• Positive Sentiment: Analyst commentary remains constructive on McKesson’s specialty distribution, oncology and technology businesses. The company’s latest reported quarter also exceeded earnings and revenue expectations, supporting the view that its core operations remain resilient. Zacks: Why retain McKesson stock
• Neutral Sentiment: McKesson Ventures’ latest report highlighted artificial intelligence, enterprise demand and investor confidence as major forces reshaping pharmaceutical technology. This could create strategic opportunities, although the report does not announce a specific financial commitment or revenue impact for MCK. McKesson Ventures pharma technology report
• Negative Sentiment: The Precision Medicine transaction comes amid a McKesson reorganization and reported layoffs. Investors may be concerned about restructuring costs, execution risk and whether the acquisition will deliver sufficient returns to offset its $2.25 billion price tag. McKesson acquisition and reorganization
• Negative Sentiment: Longer-term risks remain from drug-pricing pressure and potential healthcare-policy changes. These concerns could limit margins even as McKesson expands into higher-growth specialty and biopharmaceutical services. Zacks McKesson risks

Insider Buying and Selling

In related news, Director Bradley E. Lerman sold 301 shares of the stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $892.33, for a total transaction of $268,591.33. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Thomas L. Rodgers sold 699 shares of the business's stock in a transaction that occurred on Tuesday, June 2nd. The stock was sold at an average price of $735.27, for a total value of $513,953.73. Following the transaction, the executive vice president directly owned 2,268 shares in the company, valued at $1,667,592.36. This trade represents a 23.56% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 23,111 shares of company stock worth $18,011,274. Insiders own 0.06% of the company's stock.

McKesson Stock Down 0.8%

McKesson stock opened at $898.06 on Thursday. The stock has a market capitalization of $104.70 billion, a PE ratio of 24.03, a price-to-earnings-growth ratio of 1.78 and a beta of 0.30. McKesson Corporation has a twelve month low of $677.28 and a twelve month high of $999.00. The company has a 50 day moving average of $827.60 and a 200-day moving average of $844.17.

McKesson (NYSE:MCK - Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported $9.93 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $9.56 by $0.37. The firm had revenue of $105.38 billion during the quarter, compared to analysts' expectations of $103.88 billion. McKesson had a negative return on equity of 253.21% and a net margin of 1.12%.The company's revenue was up 7.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $8.26 EPS. McKesson has set its FY 2027 guidance at 44.200-45.000 EPS. Equities analysts anticipate that McKesson Corporation will post 44.65 EPS for the current fiscal year.

McKesson Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, October 1st. Stockholders of record on Tuesday, September 1st will be paid a dividend of $0.94 per share. The ex-dividend date is Tuesday, September 1st. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.4%. This is a positive change from McKesson's previous quarterly dividend of $0.82. McKesson's dividend payout ratio (DPR) is currently 8.78%.

McKesson Profile

McKesson Corporation NYSE: MCK is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company's core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source